updat thought lower pt tax
share under-perform market recent
includ declin past month vs
prgo may investor day share approxim
sinc investor day vs believ sector-rel
factor declin gener peer teva
turn make prgo spin gener busi potenti
less attract may factor heard number
investor think transform plan unveil last month
sound light innov reliant deal take long
time share concern believ prgo guidanc
lower consensu time releas achiev
maintain market perform rate new dcf-base price
includ billion impact on-going tax disput
new strateg plan includ coupl item sever
investor continu highlight risk relianc deal
ad new categori vape cbd prgo list
categori want explor deal prg announc
acquisit ranir global maker brand store
brand product primarili oral healthcar area travel size
known brand power toothbrush replac head
rembrandt toothpast placker floss ranir amalgam
deal four acquisit past four year vape
cbd might excit investor growth potenti
other may carri concern reput risk current cbd
oil schedul drug current accept medic use
high potenti abus accord question
addit new billion tax penalti settlement
dcf note tax entiti seek combin
billion estim may prove conserv
conserv enough depend final result assum
billion dcf per share valu would believ
tax disagr someth like someth
dismiss misunderstand base opinion
assess manag capabl time includ
prgo histori materi weak financi report
disclosur control experi recent discuss
former cfo global peer compani ignor
potenti sizabl call cash futur
overal abl make newli reduc estim
ambiti vs model howev low singl
digit top-lin growth renew deal orient execut risk
global acquisit gener spin-out potenti multi-
billion dollar tax bill keep us sidelin
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
report non-gaap adjust ep exclud one-tim item
compani data secur llc estim reuter
investor day contain lot inform main focu long-term
guidanc consum revenu growth consum oper incom growth
adjust ep growth manag dub us place
find higher growth lower multipl sector
prgo new revenu guidanc rang versu current consensu estim
new estim prgo adjust oper incom guidanc
compar consensu estim new estim
adjust ep guidanc rang note midpoint
repres declin versu prgo adjust ep declin versu
adjust ep note investor day could
upsid rang would driven item includ guidanc
includ potenti gener proair approv increment cost save and/or close ranir
acquisit also highlight investor day rx sale could result net
dilut rx spin would result dilut expect one
occur late
prgo ep guidanc rang lower consensu estim
note consensu declin approxim sinc prgo analyst day
may maintain market perform rate lower price target
roll forward discount period off-set effect downward estim
term segment guidanc expect newli name consum self america csca
net sale approxim adjust oper margin
approxim versu expect revenu oper margin
consum self-car csci compani expect revenu
adjust oper margin near approxim versu expect revenu
oper margin rx segment expect revenu
adjust oper margin around versu new expect
oper margin approxim
briefli mention also announc agre acquir privately-held ranir global
hold transact valu cash-fre debt-fre basi intend fund
acquisit cash hand rest short-term debt includ
contribut ranir guidanc expect add accret close
also announc sell anim health busi petiq cash plu
work capit adjust sale expect materi impact prgo oper
expect final within next six month
would also highlight report cash gener oper activ
approxim gener
guidanc fargo secur estimatefactset consensusnet dsg oper tax share product previou new
perrigo incom sc sc expens expens incom per perrigo compani plc
note canada pass cannabi legisl govern may embrac
price target
price target base dcf valuat includ discount rate termin
multipl integr larg part outlook carri substanti risk
risk includ turnaround brand consum healthcar busi weak rx
pharmaceut irish tax disput
believ share perform market evid emerg recent
turnaround durabl particularli relat eu busi gener busi
recent under-perform
began packag gener home remedi year later one top
over-the-count over-the-counter consum good product compani market share privat label
store brand also among lead compani pharmaceut gener market
well activ pharmaceut ingredi api market
agn thesi believ top-tier organ great pipelin domin growth franchis
sever area allergan differenti attract asset
thesi believ share under-valued current level investor under-appreci
non-xyrem relat pipelin think continu strong revenu earn growth expans
busi develop progress unappreci pipelin potenti drive
valu
